9 different filers disclosed LLY within 90 days. Disclosed 28 days after the transaction; reported as an official range, not an exact amount.
Traded Nov 11, 2025 · Filed Nov 12, 2025
A big owner of Eli Lilly sold $32.8M of Eli Lilly shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$32,828,792
Shares × reported transaction price
12 days after results of Oct 30, 2025, 85 days before results of Feb 4, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $988.62 on Nov 11, 2025, at its 52-week high, after a 30% rise over the previous 30 trading days
52-week range $625.65 (Aug 8, 2025) to $988.62 (Nov 11, 2025), 100% of the way up, from 250 adjusted closes. 30 trading days earlier: $763.00 on Sep 30, 2025. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
FDA approved Retevmo on Nov 20, 2025, 9 days after this trade.
New use approved (efficacy supplement). Active ingredient: Selpercatinib. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +2.0% | -2.9% | +4.9% |
| 30 days | +3.8% | +1.3% | +2.5% |
| 90 days | -0.8% | +3.0% | -3.7% |
| 180 days | -3.2% | +9.8% | -13.1% |
Past results only. Not a forecast.
9 different filers disclosed LLY within 90 days. Disclosed 28 days after the transaction; reported as an official range, not an exact amount.
9 different filers disclosed LLY within 90 days. Disclosed 17 days after the transaction; reported as an official range, not an exact amount.
92.4M → 92.4M shares held
A big owner of Eli Lilly sold $862K of Eli Lilly shares. Nobody planned it ahead of time.